Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2000 of 2228 entries
View as:

Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02171572 Org: User:
Start: 10/31/09 End: - Due: -

Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02276365 Org: User:
Start: 06/30/09 End: - Due: -

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT06882746 Org: User:
Start: 03/28/25 End: 05/12/27 Due: 05/12/28

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

Phase: N/A Priority: Normal
NCT ID: NCT03449381 Org: User:
Start: 06/20/18 End: 08/18/25 Due: 08/18/26

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

Phase: N/A Priority: Normal
NCT ID: NCT06139328 Org: User:
Start: 12/05/23 End: 03/15/27 Due: 03/15/28

A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib

Phase: N/A Priority: Normal
NCT ID: NCT06200714 Org: User:
Start: 07/16/24 End: 04/29/25 Due: 04/29/26

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02254720 Org: User:
Start: 09/30/06 End: - Due: -

A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations

Phase: N/A Priority: Normal
NCT ID: NCT06631417 Org: User:
Start: 10/22/24 End: 05/14/25 Due: 05/14/26

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Phase: N/A Priority: Normal
NCT ID: NCT03783000 Org: User:
Start: 01/15/19 End: 03/06/19 Due: 03/06/20

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT00060801 Org: User:
Start: 05/31/03 End: - Due: -

Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03070171 Org: User:
Start: 03/21/17 End: 06/20/17 Due: 06/20/18

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT02182024 Org: User:
Start: 04/30/05 End: - Due: -

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Phase: N/A Priority: Normal
NCT ID: NCT03764631 Org: User:
Start: 09/26/18 End: 01/11/21 Due: 01/11/22

A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma

Phase: N/A Priority: Normal
NCT ID: NCT02182661 Org: User:
Start: 07/31/98 End: - Due: -

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT01126437 Org: User:
Start: 05/31/10 End: 05/31/13 Due: 05/31/14

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02183480 Org: User:
Start: 07/31/09 End: - Due: -

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02260063 Org: User:
Start: 11/30/98 End: - Due: -

Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT02864407 Org: User:
Start: 12/19/16 End: 01/20/21 Due: 01/20/22

Trial of Afatinib in Pediatric Tumours

Phase: N/A Priority: Normal
NCT ID: NCT02372006 Org: User:
Start: 04/29/15 End: 08/05/20 Due: 08/05/21

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

Phase: N/A Priority: Normal
NCT ID: NCT00375284 Org: User:
Start: 09/30/06 End: - Due: -

Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Phase: N/A Priority: Normal
NCT ID: NCT02245503 Org: User:
Start: 05/31/03 End: - Due: -

Use of Synvisc® in Knee Osteoarthritis - Survey on Practice

Phase: N/A Priority: Normal
NCT ID: NCT02195544 Org: User:
Start: 10/31/98 End: - Due: -

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Phase: N/A Priority: Normal
NCT ID: NCT03807440 Org: User:
Start: 08/26/19 End: 08/31/21 Due: 08/31/22

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01087502 Org: User:
Start: 03/31/10 End: - Due: -

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Phase: N/A Priority: Normal
NCT ID: NCT02265679 Org: User:
Start: 10/31/01 End: - Due: -